Literature DB >> 26779785

Protothecal bursitis after simultaneous kidney/liver transplantation: a case report and review.

I Ramírez1, J F Nieto-Ríos2, C Ocampo-Kohn2, A Aristizábal-Alzate2, G Zuluaga-Valencia2, O Muñoz Maya3, J C Pérez4.   

Abstract

Solid organ transplantation is an accepted therapy for end-stage diseases of the kidneys, liver, heart, and lungs. Unfortunately, transplantation is associated with infectious complications. Here, we present a case report of Prototheca wickerhamii olecranon bursitis and review all of the cases in solid organ transplant (SOT) recipients published in the literature to date. In our patient, the infection resolved with surgical therapy and limited antifungal therapy, and no symptoms have recurred over 24 months of follow-up. A review of the literature suggests that 50% of SOT recipients with Prototheca infection present with disseminated infection, and the overall mortality is 75%. More studies are required to determine the optimal management of protothecosis in this population.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Prototheca; antifungals; olecranon bursitis; surgery; transplant

Mesh:

Year:  2016        PMID: 26779785     DOI: 10.1111/tid.12496

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  3 in total

1.  Answer to August 2018 Photo Quiz.

Authors:  Poornima Ramanan; Abinash Virk; Jennifer M Boland; Bobbi Pritt; Marco Rizzo; Nancy L Wengenack
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

2.  Systemic protothecosis in an immunocompetent patient.

Authors:  Alvano Trespalacios Sierra; Bárbara Arroyo-Salgado; Jesús Rodriguez-Blanco; Ingrid Tibocha Gordon; María Cristina Martínez-Ávila
Journal:  Trop Dis Travel Med Vaccines       Date:  2022-10-15

3.  3-Bromopyruvate as an Alternative Option for the Treatment of Protothecosis.

Authors:  Tomasz Jagielski; Katarzyna Niedźwiecka; Katarzyna Roeske; Mariusz Dyląg
Journal:  Front Pharmacol       Date:  2018-04-19       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.